GMED GLOBUS MEDICAL INC
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1237831 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.4%
TTM net income YoY31.6%
TTM EPS YoY31.4%
Revenue 3-yr CAGR36.8%
Net income 3-yr CAGR52.3%
Margins
Gross margin69.1%
Operating margin21.6%
Net margin17.8%
FCF margin24.4%
EBITDA margin28.7%
Returns
ROE12.1%
ROA10.5%
ROIC (approx.)12.9%
Asset turnover0.59x
Leverage & solvency
Liabilities / assets13.2%
Debt / equity0.00x
Current ratio4.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.66x
Accruals ratio-6.9%
Payout ratio—
Capex / revenue5.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.94B | $2.52B |
| Cost of revenue | $957.80M | $1.04B |
| Gross profit | $1.98B | $1.48B |
| R&D expense | $147.25M | $163.75M |
| SG&A expense | $1.18B | $981.36M |
| Operating income | $479.82M | $165.99M |
| Pretax income | $605.07M | $120.72M |
| Income tax | $67.20M | $17.74M |
| Net income | $537.87M | $102.98M |
| EBITDA | $756.66M | $419.38M |
| EPS (basic) | 3.98 | 0.76 |
| EPS (diluted) | 3.92 | 0.75 |
| Weighted avg. shares (diluted) | 137.06M | 137.86M |
| Banking | ||
| Net interest income | — | -$4.19M |
| Balance sheet | ||
| Cash & equivalents | $526.16M | $784.44M |
| Short-term investments | $31.09M | $105.62M |
| Receivables | $678.94M | $557.70M |
| Inventory | $759.28M | $659.23M |
| Current assets | $2.13B | $2.18B |
| PP&E, net | $564.45M | $561.91M |
| Goodwill | $1.44B | $1.43B |
| Intangibles | $745.06M | $795.12M |
| Total assets | $5.30B | $5.25B |
| Current liabilities | $498.50M | $855.91M |
| Total liabilities | $729.51M | $1.07B |
| Shareholders' equity | $4.57B | $4.18B |
| Cash flow statement | ||
| Operating cash flow | $753.45M | $520.64M |
| Capital expenditure | $164.68M | $115.43M |
| Free cash flow | $588.77M | $405.21M |
| Investing cash flow | -$355.01M | -$176.05M |
| Financing cash flow | -$679.16M | -$27.70M |
| Depreciation & amortization | $276.84M | $253.39M |
| Stock-based compensation | $49.78M | $54.19M |
| Share buybacks | $300.45M | $85.79M |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.